Ceragon (CRNT) Q1 2026 Earnings Transcript

Ceragon reported Q1 revenue of $85 million, down 4.1% year over year, but non-GAAP gross margin improved to 36% from 33.5% and free cash flow turned positive at $2.8 million. Management reaffirmed full-year 2026 revenue guidance of $355 million to $385 million and margin targets, while flagging Q2 margin pressure from India-heavy mix, a North America supply-chain delay, and FX headwinds from the shekel and rupee. Strong India bookings of about $86 million and new FR2 traction in North America support the outlook, but near-term profitability remains choppy.

Analysis

The key read-through is that Ceragon is trying to convert a cyclical revenue bridge into a structural rerating, but the market will likely focus on the sequencing risk first. India now appears to be doing the heavy lifting for the full-year plan, which is helpful for backlog visibility but dangerous for quarterly quality because it compresses reported margin exactly when the company is leaning harder into SG&A to seed private networks. That mix means earnings power may look weaker than the demand backdrop actually is, creating a setup where the stock can de-rate on near-term margin optics even if the annual model holds.

The more important second-order effect is competitive dislocation in Europe. Nokia’s divestiture is not just a share-shift story; it should lengthen decision cycles for incumbent customers while forcing multi-vendor sourcing, which tends to favor smaller specialists with deployable product now. If Ceragon can convert even a modest share of those stranded RF transmission budgets, it gets a higher-quality revenue stream with less concentration risk than India, and that is what could support a multiple expansion later in 2H26.

The North America supply issue looks genuinely transitory, but the catalyst window matters: if the fix slips beyond Q3, investors will start treating it as a hidden demand problem and discount 2027 upside from the FR2 platform. The contrarian takeaway is that the market may be underestimating how much of the 2026 narrative is already locked, while overestimating the permanence of current margin pressure. The real bear case is not guidance failure; it is that FX plus mix plus freight obscure operating leverage long enough to keep the stock range-bound until the 2027 FR2 and Europe awards become visible.

Key Decisions for Investors

• Go long CRNT on weakness over the next 1-2 weeks if the market sells the Q2 margin guide; use a 6-9 month horizon and size for a 15-25% rerating if Q3 North America revenue re-accelerates and gross margin normalizes.
• Sell out-of-the-money CRNT calls against a core long into any post-earnings bounce; near-term implied volatility should stay elevated while Q2 mix risk and FX uncertainty cap upside before Q3.
• Pair trade: long CRNT / short a more mature fixed-wireless or microwave incumbent over 3-6 months, betting that Ceragon’s India and Europe dislocation wins create a faster revenue inflection than larger peers with slower mix shift.
• For options traders, consider a CRNT January 2027 call spread to express the FR2 and North America Tier-1 monetization story; this isolates the 2027 catalyst while limiting damage if 2026 margin pressure persists longer than expected.
• Avoid shorting CRNT outright unless there is evidence the North America component issue is not resolving by late summer; the risk/reward is poor because downside is capped by backlog visibility, while upside is levered to multiple catalysts that can surface within two quarters.